Citations

Clear

499 citation(s) found for "Tracy, PB".

Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases
Reiter, Audra J. , Huang, Lynn , Craig, Brian T. , Davidoff, Andrew M. , Coggins, Jordan , Smith, Jasmine , Aldrink, Jennifer H. , Bergus, Katherine , MacArthur, Taleen A. , Polites, Stephanie F. , Boehmer, Chloé , Brungardt, Joseph G. , Arkin, Cameron, Gourmel, Antoine , Piché, Nelson , Wallace, Marshall, Liang, Jiancong , Lovvorn, Harold N. , Petroze, Robin T. , Gillies, Gwendolyn S. , Marquart, John , Becktell, Kerri , Favela, Juan , Rich, Barrie S. , Glick, Richard D. , Seemann, Natashia M. , Davidson, Jacob , Wilson, Claire A. , Roach, Jonathan P. , Doyle, Kathleen , Coakley, Brian A. , Emengo, Pamela, Merola, Pamela R., Grant, Christa N. , Tirumani, Anuritha, Dasgupta, Roshni , Wallace, Marshall W. , Aldrink, Jennifer H , Bergus, Katherine C , MacArthur, Taleen A , Malek, Marcus M , Kastenberg, Zachary J , Piche, Nelson , Becktell, Kerri , Seemann, Natashia M , Tracy, Elisabeth T , Lautz, Timothy , Dasgupta, Roshni , Arkin, Cameron , Talbot, Lindsay J , Malek, Marcus M. , Rinehardt, Hannah , Kastenberg, Zachary J. , Wallace, Marshall, Le, Hau D. , Brown, Erin G. , Tracy, Elisabeth T. , Moya‐Mendez, Mary E. , Lautz, Timothy B.

Mayo Clinic

Pediatric Blood & Cancer | April 29, 2024 | Volume: 71 | Issue: 7 | Pages: No page available

10.1002/pbc.31026 | PMID 38679864 Get It

Abstract Purpose Our objectives were to compare overall survival (OS) and pulmonary relapse between patients with metastatic Ewing sarcoma (EWS) at diagnosis who achieve rapid complete response (RCR) and those with residual pulmonary nodules after induction chemotherapy (non‐RCR). Patients and methods This retrospective cohort study included children under 20 years with metastatic EWS treated from 2007 to 2020 at 19 institutions in the Pediatric Surgical Oncology Research Collaborative. Chi‐square tests were conducted for differences among groups. Kaplan–Meier curves were generated for OS and pulmonary relapse. Results Among 148 patients with metastatic EWS at diagnosis, 61 (41.2%) achieved RCR. Five‐year OS was 71.2% for patients who achieved RCR, and 50.2% for those without RCR ( p = .04), and in multivariable regression among patients with isolated pulmonary metastases, RCR (hazards ratio [HR] 0.42; 95% confidence interval [CI]: 0.17–0.99) and whole lung irradiation (WLI) (HR 0.35; 95% CI: 0.16–0.77) were associated with improved survival. Pulmonary relapse occurred in 57 (37%) patients, including 18 (29%) in the RCR and 36 (41%) in the non‐RCR groups ( p = .14). Five‐year pulmonary relapse rates did not significantly differ based on RCR (33.0%) versus non‐RCR (47.0%, p = .13), or WLI (38.8%) versus no WLI (46.0%, p = .32). Discussion Patients with EWS who had isolated pulmonary metastases at diagnosis had improved OS if they achieved RCR and received WLI, despite having no significant differences in rates of pulmonary relapse.
Abstract 18402: Outcomes of Pacing in Patients With Cardiac Amyloidosis - A Single Center Experience
Hai, Jo Jo , Webster, Tracy L., Lin, Grace , Grogan, Martha , Brady, Peter A. , Dispenzieri, Angela

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a18402 Get It

Background: Cardiac amyloidosis (CA) is associated with sinus node dysfunction (SND) and conduction system disease (CSD) yet data on pacing indications and outcomes is scarce. Methods: Retrospective review of patients (pts) with CA who had device implantation due to pacing indication at our institution. Results: At total of 51 (mean age 67.2±9.2 years, 90.2% male) pts with immunoglobulin light chain (n=27, 52.9%), hereditary transthyretin (n=7, 13.7%) and wild-type transthyretin (n=17, 33.3%) CA were included. Indication for pacing was exercise intolerance (n=16, 31.4%), syncope (n=16, 31.4%), congestive heart failure (n=5, 9.8%) and palpitation (n=2, 3.9%) with SND (n=23, 45.1%), CSD (17=33.3%) and uncontrolled atrial fibrillation (n=11, 21.6%). 16 (31.4%) pts received defibrillators (ICD) for primary prevention, of whom 8 (15.7%) had left ventricular ejection fraction (LVEF) ≤35%. Atrial (P wave: 1.7±1.2mV, threshold: 1.1±0.5mV/0.5±0.2ms) and right ventricular (RV) (R wave: 7.9±3.8mV, threshold: 0.8±0.4mV/0.4±0.1ms) lead parameters were satisfactory at implantation. During follow-up (mean 36.6±33.6 months), 26 (51%) pts reported symptomatic improvement (SI). Syncope was the only predictor of SI (OR 16.4, 95%CI 1.8-145.2, p=0.01) while exercise intolerance was not (OR 0.09, 95%CI 0.02-0.44, p=0.003). First-time life-threatening ventricular arrhythmias (VA) occurred in 6 (11.8%) pts, 3 (5.9%) had ICD implanted for LVEF ≤35%, 3 (5.9%) without ICD and LVEF ≥35%. Syncope was not predictive of first-time VA. RV lead noise led to inappropriate ICD shocks in 1 patient. Atrial lead sensing failure occurred in 6 (11.8%) and loss of capture in 5 (9.8%). Conclusion: Device implantation in patients with cardiac amyloidosis is safe but atrial lead failure is common. Syncope usually improves with pacing whereas other factors should be considered in those presented with exercise intolerance. Selection of pts who need pacing for prophylactic ICD implantation is challenging as neither left ventricular ejection fraction nor syncope are predictive of arrhythmic events.
Abstract 14709: Right Sternal Lead Placement Increases Eligibility for Subcutaneous Defibrillator Implantation in Adults With Congenital Heart Disease
Okamura, Hideo , Bashir, Mohammad U, Webster, Tracy L., Bonnichsen, Crystal R. , Grogan, Martha , Phillips, Sabrina D. , Warnes, Carole A. , Ammash, Naser M., Connolly, Heidi M. , Friedman, Paul A. , McLeod, Christopher J.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.14709 Get It

Introduction: The subcutaneous implantable cardioverter defibrillator (S-ICD) is an attractive option for patients with congenital heart disease (CHD) in whom a transvenous system is contraindicated. However, more than 10% of adult patients with CHD fail S-ICD screening due to a large T- to R-wave ratio. We hypothesized right-sternal electrodes may permit S-ICD placement in patients who fail left-sternal screen. Methods: We prospectively screened 40 patients with CHD for S-ICD using the standard proprietary approach. We also screened with right sternal electrodes (with left can electrode position). Results: The mean age of the cohort was 46+/-15 years; 24 males were enrolled. CHD anomalies consisted of tetralogy of Fallot (n=11), Ebstein’s anomaly (n=7), atrial septal defect (n=6), dextro-looped transposition of the great artery (n=5) and other (n=11). Left side screening ECG failed in 9 patients (23%), five of whom passed with right sternal electrodes, increasing the pass rate from 77% to 90%. Figure shows the screening ECG and chest x-ray of a patient who failed in all three vectors on the left side but passed in the alternative vector on the right side and underwent right sided implantation. Conclusions: The addition of right sternal electrodes during screening increases S-ICD eligibility and may avoid thoracotomy for high risk patients with CHD.
Abstract 13545: ST2 in Heart Failure With Preserved Ejection Fraction
Stevens, Susanna R., Chen, Horng H. , Redfield, Margaret M. , AbouEzzeddine, Omar F. , McKie, Paul M. , Dunlay, Shannon M. , Felker, G. Michael , Borlaug, Barry A. , Tracy, Russell P. , Braunwald, Eugene

Mayo Clinic

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13545 Get It

Introduction: In vitro, ST2 is a marker of myocyte stress and inflammation but in vivo, there is no trans-cardiac ST2 concentration step-up to support cardiac ST2 activation in human heart failure (HF) calling into question the source of ST2 in HF. While ST2 is predictive of adverse outcomes in HF, the relationship between ST2 and key pathophysiologic domains in HF with preserved ejection fraction (HFpEF) is not well characterized. Hypothesis: ST2 levels increase in proportion to the severity of left ventricular (LV) remodeling and dysfunction in HFpEF. Methods: At enrollment, patients (n=174) from the RELAX trial testing sildenafil in HFpEF had serum ST2 levels measured and underwent assessment of pathophysiologic domains including congestion, cardiac structure and function, exercise performance (peak oxygen consumption (VO2)) and biomarkers of neurohumoral activation (NT-proBNP, aldosterone, endothelin-1), renal dysfunction (cystatin-C), fibrosis (pro-collagen III N-terminal peptide [NTP], C-telopeptide for type I collagen [CITP]), inflammation (high-sensitivity CRP [hsCRP]) and myocardial necrosis (high-sensitivity troponin-I [hsTnI]). Analysis adjusted for sex, a covariate associated with ST2 levels in normal persons. Results: See table. ST2 was associated with greater congestion, worse right ventricular (RV) pressure overload and dysfunction, lower peak VO2 and biomarkers of neurohumoral activation, renal dysfunction, fibrosis and myocardial necrosis and tended to be associated with systemic inflammation (hsCRP). ST2 was not associated with LV structure or LV systolic or diastolic function. Conclusions: In HFpEF, ST2 was associated with measures of right sided congestion, RV overload and dysfunction, exercise intolerance and other systemic markers of more advanced HF but not with LV structure or LV systolic or diastolic function. These data suggest that mechanisms distinct from LV stress stimulate ST2 activation in HFpEF.
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
Roh, Jason D. , Castro, Claire , Yu, Andy, Rana, Sarosh , Shahul, Sajid , Gray, Kathryn J. , Honigberg, Michael C. , Ricke‐Hoch, Melanie , Iwamoto, Yoshiko , Yeri, Ashish, Guerra, Justin Ralph Baldovino , Hobson, Ryan , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Lerchenmüller, Carolin , Sayed, Zeina R. Al , Verdugo, Carmen Diaz , Xia, Peng , Skarbianskis, Niv, Zeisel, Amit , Kirkland, James L. , Gorcsan, John , Damp, Julie B., Hanley‐Yanez, Karen , McNamara, Dennis M. , Investigators, for the IPAC, Rosenzweig, Anthony , Fett, James D., Pisarcik, Jessica, McTiernan, Charles F. , Alharethi, Rami , Rasmusson, Kismet, Brunisholz, Kim , Butler, Amy L., Budge, D., Kfoury, Abdallah G., Horne, Benjamin D. , Tuinei, Joe, Brown, Heather , Naftilan, Allen J., Russell, Jill , Freehardt, Darla, Hsich, Eileen , Oblak, Cynthia, Ewald, Greg, Whitehead, Donna, Flanagan, Jean, Platts, Anne, Mullin, Stephanie, Givertz, Michael M. , Anello, Mary Susan, Booth, David R. , Sandlin, Tiffany, Wijesiri, Wendy, Blauwet, Lori A., Brunner, Joann, Phelps, Mary, Kempf, Ruth, Modi, Kalgi , Norwood, Tracy, Griza, Decebal Sorin, Adams, Patricia L., Thohan, Vinay , Wesley-Farrington, Deborah, Soots, Sandra, Sheppard, Richard , Lapointe, Nathalie, Nathaniel, Heather, Kealey, Angela, Semigran, Marc J., Daher, Maureen, Silber, David, Popjes, Eric , Frey, Patricia, Nicklas, Todd, Alexis, Jeffrey D. , Caufield, Lori, Thornton, John W., Gentry, Mindy, Robinson, V.J. , Sharma, Gyanendra K. , Holloway, Joan, Powell, Maria, Markham, David W. , Fernandez, Lynn, Gimovsky, Martin L., Hochbaum, Natalia, Patel, Bharati Kadamb , Adams, Laura , Ramani, Gautam , Robinson, Shawn , Fisher, Stacy D. , Marshall, Joanne, Haythe, Jennifer , Mancini, Donna , Bijou, Rachel, Marks, Marybeth, Arango, Henry, Bolos, Mariana, Mather, Paul , Rubin, Sharon, Bonita, Raphael , Eberwine, Susan, Skopicki, Hal A. , Stergiopoulos, Kathleen , McCathy-Santoro, Ellen, Intravaia, Jennifer, Maas, Elizabeth W., Safirstein, Jordan, Martinez, Nancy , Corpoin, Christine, Hesari, Donna, Chaparro, Sandra , Hudson, Laura J., Ghali, Jalal K. , Injic, Zora, Wittstein, Ilan S. , Kitchen, Robert , Guerra, Justin Baldovino , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Al Sayed, Zeina R , Diaz Verdugo, Carmen , Xia, Peng , Zeisel, Amit , Bauersachs, Johann , Kirkland, James L , Karumanchi, S Ananth , Gorcsan, John , Sugahara, Masataka , Hanley-Yanez, Karen , Ellinor, Patrick T , Arany, Zoltan Pierre , McNamara, Dennis M , Rosenzweig, Anthony , Honigberg, Michael C , Castro, Claire , Karumanchi, S. Ananth , Ellinor, Patrick T. , Investigators, for the IPAC, Hilfiker‐Kleiner, Denise , Schelbert, Erik B. , Butler, Amy, Elkayam, Uri , Caro, Jorge , Rajagopalan, Navin , Booth, David, Cooper, Leslie T. , Briller, Joan Ellen , Felker, G. Michael , Kociol, Robb D. , Adams, Patricia, Wells, Gretchen , Michel, Caroline, Boehmer, John , Holloway, Joan, Powell, Maria, Drazner, Mark H. , Zucker, Mark Jay , Baran, David A. , Patel, Bharati, Gottlieb, Stephen S. , Farr, Maryjane , Bozkurt, Biykem , Maas, Elizabeth, Kleet, Audrey

Mayo Clinic

Science Translational Medicine | April 17, 2024 | Volume: 16 | Issue: 743 | Pages: No page available

10.1126/scitranslmed.adi0077 | PMID 38630848 Get It

Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator–activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101
Batchelor, Tracy T. , Giri, Sharmila, Ruppert, Amy S. , Geyer, Susan M. , Smith, Scott E. , Mohile, Nimish, Swinnen, Lode J., Friedberg, Jonathan W. , Kahl, Brad S. , Bartlett, Nancy L. , Cheson, Bruce D. , Wagner‐Johnston, Nina D. , Nayak, Lakshmi , Leonard, John P. , Rubenstein, James L. , Hsi, Eric D , Wagner-Johnston, Nina , Bartlett, Nancy L , Kahl, Brad S , Hsi, Eric D.

Mayo Clinic

Blood Advances | April 10, 2024 | Volume: 8 | Issue: 12 | Pages: 3189-3199

10.1182/bloodadvances.2023011657 | PMID 38598710 Get It

Abstract Although it is evident that standard-dose whole-brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We performed a randomized phase 2 clinical trial via the US Alliance cancer cooperative group to compare myeloablative consolidation supported by autologous stem cell transplantation with nonmyeloablative consolidation after induction therapy for PCNSL. To our knowledge, this is the first randomized trial to be initiated that eliminates whole-brain radiotherapy as a consolidative approach in newly diagnosed PCNSL. Patients aged 18 to 75 years were randomly assigned in a 1:1 manner to induction therapy (methotrexate, temozolomide, rituximab, and cytarabine) followed by consolidation with either thiotepa plus carmustine and autologous stem cell rescue vs induction followed by nonmyeloablative, infusional etoposide plus cytarabine. The primary end point was progression-free survival (PFS). A total of 113 patients were randomized, and 108 (54 in each arm) were evaluable. More patients in the nonmyeloablative arm experienced progressive disease or death during induction (28% vs 11%; P = .05). Thirty-six patients received autologous stem cell transplant, and 34 received nonmyeloablative consolidation. The estimated 2-year PFS was higher in the myeloablative vs nonmyeloablative arm (73% vs 51%; P = .02). However, a planned secondary analysis, landmarked at start of the consolidation, revealed that the estimated 2-year PFS in those who completed consolidation therapy was not significantly different between the arms (86% vs 71%; P = .21). Both consolidative strategies yielded encouraging efficacy and similar toxicity profiles. This trial was registered at www.clininicals.gov as #NCT01511562.
Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske, Hannah W. , Shah, Samir A. , Al-Bawardy, Badr , Binion, David G. , Bohm, Matthew , Brand, Myron, Cohen, Benjamin L, Dueker, Jeffrey, Engels, Michael , Fine, Sean , Förster, E , Gaidos, Jill , Ginsburg, Philip, Goyal, Alka , Hanson, John S. , Herfath, Hans, Hull, Tracy L. , Kelly, Colleen , Lazarev, Mark , Levy, L. Campbell, Melia, Joanna , Philpott, Jessica, Qazi, Taha , Watson, Andrew , Wexner, Steven D. , Williams, Emmanuelle, Al‐Bawardy, Badr , Al-Bawardy, Badr , Bohm, Matthew , Fine, Sean , Forster, Erin , Gaidos, Jill K J , Hull, Tracy , Melia, Joanna , Qazi, Taha , Regueiro, Miguel , Wexner, Steven D , Ward, Chris , Holubar, Stefan D. , Barnes, Edward L. , Clarke, Kofi , Cohen, Benjamin L, Cross, Raymond K. , Farraye, Francis A. , Hanson, John, Philpott, Jessica R., Siegel, Corey A , Regueiro, Miguel

Mayo Clinic

Crohn's & Colitis 360 | April 10, 2024 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/crocol/otae022 | PMID 38720935 Get It

Abstract Background Since 2009, inflammatory bowel disease (IBD) specialists have utilized “IBD LIVE,” a weekly live video conference with a global audience, to discuss the multidisciplinary management of their most challenging cases. While most cases presented were confirmed IBD, a substantial number were diseases that mimic IBD. We have categorized all IBD LIVE cases and identified “IBD-mimics” with consequent clinical management implications. Methods Cases have been recorded/archived since May 2018; we reviewed all 371 cases from May 2018–February 2023. IBD-mimics were analyzed/categorized according to their diagnostic and therapeutic workup. Results Confirmed IBD cases made up 82.5% (306/371; 193 Crohn’s disease, 107 ulcerative colitis, and 6 IBD-unclassified). Sixty-five (17.5%) cases were found to be mimics, most commonly medication-induced (n = 8) or vasculitis (n = 7). The evaluations that ultimately resulted in correct diagnosis included additional endoscopic biopsies (n = 13, 21%), surgical exploration/pathology (n = 10, 16.5%), biopsies from outside the GI tract (n = 10, 16.5%), genetic/laboratory testing (n = 8, 13%), extensive review of patient history (n = 8, 13%), imaging (n = 5, 8%), balloon enteroscopy (n = 5, 8%), and capsule endoscopy (n = 2, 3%). Twenty-five patients (25/65, 38%) were treated with biologics for presumed IBD, 5 of whom subsequently experienced adverse events requiring discontinuation of the biologic. Many patients were prescribed steroids, azathioprine, mercaptopurine, or methotrexate, and 3 were trialed on tofacitinib. Conclusions The diverse presentation of IBD and IBD-mimics necessitates periodic consideration of the differential diagnosis, and reassessment of treatment in presumed IBD patients without appropriate clinical response. The substantial differences and often conflicting treatment approaches to IBD versus IBD-mimics directly impact the quality and cost of patient care.
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study
Crane, Genevieve M. , Geyer, Julia T. , Wang, Sa A. , Li, Ke David, Davis, Adam R. , Bosler, David , Bueso‐Ramos, Carlos E. , Bagg, Adam , Hasserjian, Robert P. , Hsi, Eric D , Thakral, Beenu , Wool, Geoffrey D. , Boiocchi, Leonardo , Arber, Daniel A. , George, Tracy I. , Orazi, Attilio , Hsi, Eric D. , Rogers, Heesun J.

Mayo Clinic

American Journal of Clinical Pathology | April 10, 2024 | Volume: 162 | Issue: 3 | Pages: 233-242

10.1093/ajcp/aqae033 | PMID 38597584 Get It

Abstract Objectives Myeloproliferative neoplasm, unclassifiable (MPN-U, revised to MPN, not otherwise specified in the fifth edition of the World Health Organization classification) is a heterogeneous category of primary marrow disorders with clinical, morphologic, and/or molecular features that preclude classification as a more specific MPN subtype due to stage at diagnosis, overlapping features between MPN subtypes, or the presence of coexisting disorders. Compared with other MPN subtypes, the contribution of the mutational landscape in MPN-U in conjunction with other clinical and morphologic biomarkers to prognosis has been less well investigated. Methods We performed a multicenter, retrospective study of MPN-U (94 cases) to better define the clinicopathologic features, genetic landscape, and clinical outcomes, including subgroups of early-stage, advanced-stage, and coexisting disorders. The Dynamic International Prognostic Scoring System (DIPSS) plus scoring system was applied to assess its relevance to MPN-U prognosis. Results Multivariate analysis demonstrated bone marrow blast count and DIPSS plus score as statistically significant in predicting overall survival. Univariate analysis identified additional potential poor prognostic markers, including abnormal karyotype and absence of JAK2 mutation. Secondary mutations were frequent in the subset analyzed by next-generation sequencing (26/37 cases, 70.3%) with a borderline association between high molecular risk mutations and overall survival. Conclusions This study, as one of the largest of MPN-U studies incorporating both clinicopathologic and molecular data, moves toward identification of biomarkers that better predict prognosis in this heterogeneous category.
Non-affirmation minority stress, internalized transphobia, and subjective cognitive decline among transgender and gender diverse veterans aged 45 years and older
Jeon, Amy, Simpson, Tracy L. , Eleazer, Jacob , Jasuja, Guneet K. , Blosnich, John R. , Eleazer, Jacob R , Wolfe, Hill L. , Goulet, Joseph Lucien , Kauth, Michael R. , Shipherd, Jillian C. , Littman, Alyson J.

Mayo Clinic

Aging & Mental Health | April 3, 2024 | Volume: 28 | Issue: 10 | Pages: 1357-1363

10.1080/13607863.2024.2335565 | PMID 38567655 Get It

Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
Kastenberg, Zachary J. , Short, Scott S. , Riehle, Kimberly J. , Lautz, Timothy B. , Ott, Katherine C. , Murphy, Andrew J. , Mansfield, Sara A. , Hallis, Brian, Murphy, Joseph, Roach, Jonathan P. , Polites, Stephanie F. , Beckhorn, Catherine B , Fialkowski, Elizabeth , Seemann, Natashia M. , Bütter, Andreana , Rich, Barrie S. , Glick, Richard D. , Bondoc, Alex, Ofori-Atta, Blessing , Zamora, Abigail K., Vasudevan, Sanjeev A. , Rinehardt, Hannah , Lapidus‐Krol, Eveline , Meyers, Rebecka L. , Tiao, Greg , Dasgupta, Roshni , Baertschiger, Reto M. , Lautz, Timothy , Murphy, Andrew J , Beckhorn, Catherine , Tracy, Elisabeth T , Fialkowski, Elizabeth A , Seemann, Natashia M , Malek, Marcus M , Baertschiger, Reto , Kastenberg, Zachary J , Dasgupta, Roshni , Utria, Alan Fremder , Lal, Dave R. , Tracy, Elisabeth T. , Bondoc, Alexander , Presson, Angela P. , Chen, Stephanie , Kim, Eugene S. , Malek, Marcus M. , Putra, Juan , Superina, Riccardo Antonio , Langham, Max Raymond

Mayo Clinic

Pediatric Blood & Cancer | April 1, 2024 | Volume: 71 | Issue: 6 | Pages: No page available

10.1002/pbc.30975 | PMID 38556718 Get It

AbstractBackgroundUndifferentiated embryonal sarcoma of the liver (UESL) is a rare tumor for which there are few evidence‐based guidelines. The aim of this study was to define current management strategies and outcomes for these patients using a multi‐institutional dataset curated by the Pediatric Surgical Oncology Research Collaborative.MethodsData were collected retrospectively for patients with UESL treated across 17 children's hospitals in North America from 1989 to 2019. Factors analyzed included patient and tumor characteristics, PRETEXT group, operative details, and neoadjuvant/adjuvant regimens. Event‐free and overall survival (EFS, OS) were the primary and secondary outcomes, respectively.ResultsSeventy‐eight patients were identified with a median age of 9.9 years [interquartile range [IQR): 7–12]. Twenty‐seven patients underwent resection at diagnosis, and 47 patients underwent delayed resection, including eight liver transplants. Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm [IQR: 0.0–4.4] and greater than 90% tumor necrosis in 79% of the patients undergoing delayed resection. R0 resections were accomplished in 63 patients (81%). Univariate analysis found that metastatic disease impacted OS, and completeness of resection impacted both EFS and OS, while multivariate analysis revealed that R0 resection was associated with decreased expected hazards of experiencing an event [hazard ratio (HR): 0.14, 95% confidence interval (CI): 0.04–0.6]. At a median follow‐up of 4 years [IQR: 2–8], the EFS was 70.0% [95% CI: 60%–82%] and OS was 83% [95% CI: 75%–93%].ConclusionComplete resection is associated with improved survival for patients with UESL. Neoadjuvant chemotherapy causes minimal radiographic response, but significant tumor necrosis.